Literature DB >> 1579296

Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.

A P Makar1, G B Kristensen, J Kaern, O P Børmer, V M Abeler, C G Tropé.   

Abstract

The prognostic significance of the serum CA 125 level was studied in 687 patients with invasive epithelial ovarian malignancies. The samples were collected preoperatively in 200 and postoperatively in 487 patients. Median follow-up was 27 months (range 3-84). The serum CA 125 level was elevated preoperatively in 90% of cases, with a median value of 429 U/mL. In patients with evidence of disease at the time of sampling, the CA 125 serum level correlated directly to tumor stage, tumor load, and histologic grade. Using Cox multivariate analysis, the preoperative serum CA 125 level had no independent prognostic significance, whereas the postoperative level did. In patients without residual disease after primary surgery, histologic type (P less than .0001), postoperative CA 125 level with 35 U/mL as the cutoff value (P = .0009), and tumor grade (P = .034) were independent prognostic factors for survival. For those with residual tumor after primary surgery, histologic type (P less than .0001), postoperative treatment (P = .0002), size of residual disease (P = .0005), and postoperative serum CA 125 level with 65 U/mL as a cutoff (P = .003) were independent prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579296

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  21 in total

1.  Correlates of the preoperative level of CA125 at presentation of ovarian cancer.

Authors:  Daniel W Cramer; Allison F Vitonis; William R Welch; Kathryn L Terry; Annekathryn Goodman; Bo R Rueda; Ross S Berkowitz
Journal:  Gynecol Oncol       Date:  2010-09-17       Impact factor: 5.482

2.  Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer.

Authors:  Sernaz Uzunoglu; Aysun Aybatlı; Petek Balkanlı Kaplan; Irfan Cicin; Necdet Sut; Cenk Sayın; Fusun Varol
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

3.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

4.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

Review 5.  The rise of genomic profiling in ovarian cancer.

Authors:  Rebecca A Previs; Anil K Sood; Gordon B Mills; Shannon N Westin
Journal:  Expert Rev Mol Diagn       Date:  2016-12       Impact factor: 5.225

6.  Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Mi-Ok Lyu; Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

7.  Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses.

Authors:  Serhat Sen; Oğuzhan Kuru; Ozgür Akbayır; Hilal Oğuz; Vildan Yasasever; Sinan Berkman
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-12-01

Review 8.  Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Authors:  Amin P Makar; Claes G Tropé; Philippe Tummers; Hannelore Denys; Katrien Vandecasteele
Journal:  Oncologist       Date:  2016-03-23

9.  Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.

Authors:  Yong Soon Kwon; Joo-Hyun Nam; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong Man Kim; Young Tak Kim
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

10.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.